Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
Andronis L, Goranitis I, Pirrie S, Pope A, Barton D, Collins S, Daunton A, McLaren D, O'Sullivan JM, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown JE, Chakraborti P, Hussain SA, Russell JM, Billingham LJ, James ND.
Andronis L, et al. Among authors: james nd.
BJU Int. 2017 Apr;119(4):522-529. doi: 10.1111/bju.13549. Epub 2016 Jul 10.
BJU Int. 2017.
PMID: 27256016
Free article.
Clinical Trial.